Market Overview

Jefferies Reiterates Hold Rating, $6 PT for Exelixis

Share:
Related EXEL
Watch These 7 Huge Put Purchases In Friday Trade
Major Averages Close Thursday's Session Mostly Unchanged
A Merck Versus Bristol Showdown (Seeking Alpha)

In a company update published earlier today, Jefferies & Company, Inc. reiterated its Hold rating and $6.00 price target for Exelixis, Inc. (NASDAQ: EXEL), related to the recent reveal of cabo NRE efficacy data.

Jefferies went on to say “The cabo NRE data, somewhat key for the mCRPC outlook and presented at ASCO, left much to be desired. Despite somewhat intriguing early data in renal and liver cancers for which further exploration is warranted, we remain concerned about cabo's clinical, regulatory and commercial prospects in mCRPC, where investor and EXEL's focus lies.”

Exelixis, Inc. closed yesterday at $4.77.

Latest Ratings for EXEL

DateFirmActionFromTo
Aug 2016Stifel NicolausMaintainsBuy
Apr 2016Stifel NicolausUpgradesHoldBuy
Jan 2016Leerink SwannUpgradesMarket PerformOutperform

View More Analyst Ratings for EXEL
View the Latest Analyst Ratings

Posted-In: Jefferies & Company Inc.Analyst Color Reiteration Analyst Ratings

 

Related Articles (EXEL)

View Comments and Join the Discussion!